96 related articles for article (PubMed ID: 11910332)
21. Intensity-modulated whole abdomen irradiation following adjuvant carboplatin/taxane chemotherapy for FIGO stage III ovarian cancer : four-year outcomes.
Rochet N; Lindel K; Katayama S; Schubert K; Herfarth K; Schneeweiss A; Sohn C; Harms W; Debus J
Strahlenther Onkol; 2015 Jul; 191(7):582-9. PubMed ID: 25786589
[TBL] [Abstract][Full Text] [Related]
22. Differential platelet levels affect response to taxane-based therapy in ovarian cancer.
Bottsford-Miller J; Choi HJ; Dalton HJ; Stone RL; Cho MS; Haemmerle M; Nick AM; Pradeep S; Zand B; Previs RA; Pecot CV; Crane EK; Hu W; Lutgendorf SK; Afshar-Kharghan V; Sood AK
Clin Cancer Res; 2015 Feb; 21(3):602-10. PubMed ID: 25473001
[TBL] [Abstract][Full Text] [Related]
23. Platinum resistance and impaired survival in patients with advanced primary peritoneal carcinoma: matched-case comparison with patients with epithelial ovarian carcinoma.
Eisenhauer EL; Sonoda Y; Levine DA; Abu-Rustum NR; Gemignani ML; Sabbatini PJ; Barakat RR; Chi DS
Am J Obstet Gynecol; 2008 Feb; 198(2):213.e1-7. PubMed ID: 18226627
[TBL] [Abstract][Full Text] [Related]
24. Impact of combination chemotherapy with itraconazole on survival of patients with refractory ovarian cancer.
Tsubamoto H; Sonoda T; Yamasaki M; Inoue K
Anticancer Res; 2014 May; 34(5):2481-7. PubMed ID: 24778064
[TBL] [Abstract][Full Text] [Related]
25. A cost-effectiveness analysis of chemotherapy for patients with recurrent platinum-sensitive epithelial ovarian cancer.
Case AS; Rocconi RP; Partridge EE; Straughn JM
Gynecol Oncol; 2007 Apr; 105(1):223-7. PubMed ID: 17215031
[TBL] [Abstract][Full Text] [Related]
26. Is taxane/platinum/5 fluorouracil superior to taxane/platinum alone and does docetaxel trump paclitaxel in induction therapy for locally advanced oral cavity cancers?
Noronha V; Patil V; Joshi A; Muddu V; Bhattacharjee A; Juvekar S; Arya S; Chaturvedi P; Chaukar D; Pai PS; Dcruz AK; Prabhash K
Indian J Cancer; 2015; 52(1):70-3. PubMed ID: 26837979
[TBL] [Abstract][Full Text] [Related]
27. Neo-adjuvant chemotherapy in advanced hypopharyngeal carcinoma.
Joshi P; Patil V; Joshi A; Norohna V; Chaturvedi P; Chaukar D; Pai P; Nair D; Juvekar S; Agarwal JP; D'Cruz AK; Prabhash K
Indian J Cancer; 2013; 50(1):25-30. PubMed ID: 23713041
[TBL] [Abstract][Full Text] [Related]
28. High-dose chemotherapy and hematopoietic progenitor cell support for patients with epithelial ovarian cancer.
Kotz KW; Schilder RJ
Semin Oncol; 1995 Jun; 22(3):250-62. PubMed ID: 7777869
[No Abstract] [Full Text] [Related]
29. [CA-125 antigen].
Zakrzewska I
Postepy Hig Med Dosw; 2002; 56(1):29-38. PubMed ID: 11987487
[TBL] [Abstract][Full Text] [Related]
30. A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer.
Clamp A; Adams M; Atkinson R; Boven E; Calvert AH; Cervantes A; Ganesan T; Lotz J; Vasey P; Cheverton P; Jayson GC
Gynecol Oncol; 2004 Oct; 95(1):114-9. PubMed ID: 15385119
[TBL] [Abstract][Full Text] [Related]
31. [Chemotherapy for prostate cancer].
Itoh N
Nihon Rinsho; 2005 Feb; 63(2):293-7. PubMed ID: 15714981
[TBL] [Abstract][Full Text] [Related]
32. Surveillance for the detection of recurrent ovarian cancer: survival impact or lead-time bias?
Tanner EJ; Chi DS; Eisenhauer EL; Diaz-Montes TP; Santillan A; Bristow RE
Gynecol Oncol; 2010 May; 117(2):336-40. PubMed ID: 20153027
[TBL] [Abstract][Full Text] [Related]
33. Induction therapy in the modern era of combined-modality therapy for locally advanced head and neck cancer.
Posner M; Vermorken JB
Semin Oncol; 2008 Jun; 35(3):221-8. PubMed ID: 18544437
[TBL] [Abstract][Full Text] [Related]
34. Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6).
Wagner U; du Bois A; Pfisterer J; Huober J; Loibl S; Lück HJ; Sehouli J; Gropp M; Stähle A; Schmalfeldt B; Meier W; Jackisch C;
Gynecol Oncol; 2007 Apr; 105(1):132-7. PubMed ID: 17161453
[TBL] [Abstract][Full Text] [Related]
35. Phase 2 trial of prolonged administration of oral topotecan in platinum/taxane-refractory ovarian, fallopian tube, and primary peritoneal cancers.
Markman M; Webster K; Zanotti K; Kulp B; Peterson G; Belinson J
Gynecol Oncol; 2004 Oct; 95(1):109-13. PubMed ID: 15385118
[TBL] [Abstract][Full Text] [Related]
36. The role of ultrasound and tumour markers in the early detection of ovarian cancer.
Oram DH; Jeyarajah AR
Br J Obstet Gynaecol; 1994 Nov; 101(11):939-45. PubMed ID: 7999723
[No Abstract] [Full Text] [Related]
37. [The role of tumor marker CA 125 in the treatment of ovarian cancer].
Porsbjerg CM; Sørensen JB; Lund BA
Ugeskr Laeger; 1998 Feb; 160(7):995-1000. PubMed ID: 9477746
[TBL] [Abstract][Full Text] [Related]
38. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.
Sessa C; De Braud F; Perotti A; Bauer J; Curigliano G; Noberasco C; Zanaboni F; Gianni L; Marsoni S; Jimeno J; D'Incalci M; Dall'ó E; Colombo N
J Clin Oncol; 2005 Mar; 23(9):1867-74. PubMed ID: 15774779
[TBL] [Abstract][Full Text] [Related]
39. Straight talk about ovarian cancer.
Martin VR
Nursing; 2005 Apr; 35(4):36-41; quiz 42. PubMed ID: 15818250
[TBL] [Abstract][Full Text] [Related]
40. [Ovarian cancer].
Langmár Z; Csömör S; Németh M; Tomcsik Z; Joó JG
Orv Hetil; 2011 Dec; 152(49):1977-84. PubMed ID: 22106167
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
